LPTX leaptx.com: Projected Price to Earnings

LPTX (Leap Therapeutics, Inc.) - company brandmark

High clinic demand for targeted therapy for solid tumors determines the cost structure of Leap Therapeutics, Inc. (LPTX). The business's forward P/E on the GURU.Markets chart demonstrates a balance of these expenses, where the 0.00 metric reflects current dynamics. Development is based on immuno-oncology markets for patients with chemotherapy resistance, while growth is driven by the success of the DKN-01 drug and the expansion of therapeutic indications.

Leap Therapeutics, Inc. - LPTX Future Price to Earnings Multiple (period 07/04/2022 - 11/13/2025)

Metric breakdowns and analytics for leaptx.com (LPTX)

Fundamental company analysis:Leap Therapeutics Inc LPTX
Signature product of Leap Therapeutics, Inc.

Forward P/E measures a stock's market value relative to expected earnings per share, allowing for an assessment of the premium paid for future business growth. By analyzing the forward P/E history of Leap Therapeutics, Inc. (LPTX), an investor compares market expectations with the commercialization potential of the DKN-01 therapy for gastrointestinal cancers, which determines the fundamental stability and quality of the investment asset.

Analysis of competing companies

Forward P/E Multiple IBRX|Immunocore Holdings plc (IMCR) - Forward Price to Earnings Multiple|Janux Therapeutics Inc - Projected Price to Earnings|Arcus Biosciences (RCUS) - Projected Price to Earnings Ratio|ZYME: Projected Price to Earnings|Future Price to Earnings Multiple TNGX (Tango Therapeutics, Inc.)|IOVA: Forward P/E Multiple|IMTX - Market Cap to Projected Earnings|Future Price to Earnings xencor.com|Projected Price to Earnings compasstherapeutics.com (CMPX)|Future Price to Earnings Replimune Group Inc (REPL)|Projected Price to Earnings Lyell Immunopharma Inc LYEL|Innate Pharma SA - Projected Price to Earnings|Forward P/E Multiple Pyxis Oncology, Inc. PYXS|CGEN - Future Price to Earnings|IOBT (iobiotech.com) - Price to Future Earnings Ratio|Sutro Biopharma, Inc (STRO) - Future Price to Earnings|Projected Price to Earnings Ratio MiNK (INKT)|Projected Price to Earnings HOWL|IMMX - Forward Price to Earnings Multiple|Projected Price to Earnings ALXO (ALX Oncology Holdings)|CUE (Cue Biopharma) - Future Price to Earnings Multiple|Forward P/E Multiple PDSB (PDS Biotechnology)|Future Price to Earnings Multiple SONN|MAIABiotech.com - Forward P/E Multiple|Projected Price to Earnings Ratio Liminatus|Lava Tx (LVTX) - Future Price to Earnings|NextCure, Inc. - Future Price to Earnings Multiple|INTS (Intensity Tx) - Forward P/E Multiple|Forward P/E Multiple senseibio.com|Future Price to Earnings Theriva Biologics (TOVX)|GRTS: Price to Expected Earnings Ratio|Forward P/E Multiple KA (kinetabio.com)|neximmune.com (NEXI) - Projected Price to Earnings Ratio|TSBX: Projected Price to Earnings|VCNX: Future Price to Earnings|HARP: Forward P/E Multiple